The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarillion Plc Regulatory News (CLLN)

  • This share is currently suspended. It was suspended at a price of 14.27

Share Price Information for Carillion Plc (CLLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.27
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.27
CLLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update

17 Nov 2017 07:02

RNS Number : 8037W
Carillion PLC
17 November 2017
 

17 November 2017

Update on discussions with stakeholders, trading and financial covenants deferral

Carillion plc ("Carillion" or "the Group") today provides an update on discussions with its financial stakeholders, trading and its intention to seek to defer the testing of its financial covenants.

Since July, the Group has been focused on reducing costs, collecting cash, executing its disposals programme and implementing its new operating model. These self-help measures will serve to reduce the Group's average net debt over time, but they will not be sufficient to enable the Group to achieve its target net debt to EBITDA ratio of between 1.0 to 1.5 times by the end of 2018. The Board is therefore in discussions with stakeholders regarding a broad range of options to further reduce net debt and repair and strengthen the Group's balance sheet. This will require some form of recapitalisation, which could involve a restructuring of the balance sheet. The Board expects to commence steps to implement the chosen option during the first quarter of 2018 and a further announcement will be made in due course.

In its interim results on 29 September 2017, Carillion confirmed that it was forecast to be in compliance with its financial covenants as at 31 December 2017. As then indicated, compliance with its financial covenants was dependent on achieving its underlying forecasts, which assume that the normal pattern of receipts and payments continue alongside the completion of a number of PPP disposals and settlement receipts on contracts.

The Board has kept under continuous review the risk that receipts from contract claims and/or disposals forecast to be received during November and December 2017 might slip beyond 31 December 2017. The Group now expects that a combination of delays to certain PPP disposals, a slippage in the commencement date of a significant project in the Middle East and lower than expected margin improvements across a small number of UK Support Services contracts, partially offset by cost savings initiatives realised in the fourth quarter, will lead to profits for the year to 31 December 2017 being materially lower than current market expectations. Given the impact of delays in receipts and disposals, the Group now expects full year average net borrowing in 2017 to be between £875m and £925m.

Based on its latest forecasts, reflecting the items mentioned above, the Board now expects a covenant breach as at 31 December 2017. Following discussions with its principal lenders and with their support, the Board has concluded that it is necessary to amend the relevant agreements to defer the test date for both its financial covenants from 31 December 2017 to 30 April 2018 (based on EBITDA for the 12 months to that date), by which time it expects to be implementing its recapitalisation plan. Carillion has now commenced a process to seek the consents necessary to make this amendment.

Commenting, Interim Chief Executive, Keith Cochrane said:

"Whilst we continue to target cash collections, reduce costs, execute disposals and focus on delivering for our customers, it is clear that significant challenges remain and more needs to be done to reduce net debt and rebuild the balance sheet. Constructive dialogue is continuing with our financial stakeholders, and I am grateful for their support. I remain focused on addressing this issue before my successor, Andrew Davies, takes up the role on 2 April 2018."

This and other Carillion news releases can be found at www.carillionplc.com.

 

For more information

Kellie McAvoy, Head of Investor Relations, or,

John Denning, Director Group Corporate Affairs, Carillion plc +44 (0) 1902 906333

 

 

 

Teneo Blue Rubicon

Fraser Hardie/Charles Armitstead/Haya Herbert-Burns +44 (0) 207 420 3197

 

Notes to editors

 

Financial covenants

Certain of Carillion's financing arrangements contain financial covenants that leverage (net debt / EBITDA) will be no more than 3.5 times and that interest cover (trading cashflow / net interest pre-IAS 19 charges) will be not less than 3.5 times.

 

Financing arrangements

The relevant financing arrangements are Carillion's senior additional funding facilities, syndicated revolving credit facility, private placement notes, Schuldschein loans, committed bonding lines and committed bilateral facilities.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFXFEEXFEF
Date   Source Headline
3rd Apr 20187:30 amRNSUpdate re Liquidation of Carillion
19th Mar 20187:00 amRNSFRC investigation
17th Jan 20188:15 amRNSAnnouncement Re. Carillion PLC
15th Jan 20187:45 amRNSSuspension - Carillion PLC
15th Jan 20187:00 amRNSCompulsory liquidation of Carillion
12th Jan 20186:08 pmRNSUpdate on discussions with creditors
12th Jan 20185:08 pmRNSHolding(s) in Company
10th Jan 20185:48 pmRNSHolding(s) in Company
9th Jan 20187:03 amRNSResponse to share price movement
3rd Jan 20184:44 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSRegulatory investigation
22nd Dec 20177:00 amRNSUpdate on financial covenant deferral
20th Dec 201710:16 amRNSBlock listing Interim Review
20th Dec 20177:00 amRNSChief Executive Appointment
13th Dec 20177:00 amRNSUpdate on UK healthcare facilities business
11th Dec 20177:58 amRNSHolding(s) in Company
1st Dec 20177:00 amRNSDirectorate Change
23rd Nov 201712:08 pmRNSHolding(s) in Company
22nd Nov 201712:29 pmRNSHolding(s) in Company
21st Nov 20174:11 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFramework Award
17th Nov 20177:02 amRNSUpdate
15th Nov 20177:00 amRNSOman - letter of award for contract
6th Nov 20177:00 amRNSContract wins
2nd Nov 20177:00 amRNSDirectorate Change
31st Oct 20177:00 amRNSDisposal
27th Oct 20177:00 amRNSChief Executive Appointment
24th Oct 20177:00 amRNSUpdate on financing, disposals and work winning
12th Oct 201712:43 pmRNSUK Healthcare business
4th Oct 20172:58 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSHalf-year Report
22nd Sep 20171:00 pmRNSHolding(s) in Company
19th Sep 20174:55 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:17 pmRNSAnnouncement of 2017 interim results
17th Aug 20174:19 pmRNSHolding(s) in Company
15th Aug 20175:58 pmRNSHolding(s) in Company
11th Aug 20176:20 pmRNSHolding(s) in Company
8th Aug 20173:59 pmRNSHolding(s) in Company
8th Aug 201710:02 amRNSHolding(s) in Company
3rd Aug 20179:02 amRNSHolding(s) in Company
1st Aug 201712:24 pmRNSHolding(s) in Company
31st Jul 20172:57 pmRNSHolding(s) in Company
27th Jul 20176:28 pmRNSHolding(s) in Company
18th Jul 201710:49 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSCarillion JV awarded two further HESTIA contracts
17th Jul 20177:19 amRNSHS2 Contract Award
17th Jul 20177:00 amRNSCarillion appoints EY to support strategic review
14th Jul 201712:20 pmRNSHolding(s) in Company
14th Jul 20177:00 amRNSAppointment of Joint Financial Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.